Telmisartan decreased NO production in LPS-stimulated BV2 and primary neonatal rat glial cells. by Nofar Torika (3169497)

PRL decreased the proapoptotic ratio Bax/Bcl-2 in hippocampal neurons exposed with Glu. by Nadia A. Rivero-Segura (4006709)

Measurement of the mitochondrial superoxide anion production in HL-1 cells exposed to LG, NG, HG and IHG between short- (12h) and long-time (72h) glucose treatment. by Patrick Mordel (17020879)

Comparison of oxidized proteins extracted from HL-1 cells exposed to LG, NG, HG and IHG between short- (12h) and long-time (72h) glucose treatment. by Patrick Mordel (17020879)

Time adjusted survival curves for high vs. low renalase among patients with COVID-19 disease (using first quartile as cutoff). by Basmah Safdar (12213257)

Cox hazard regression model of renalase and primary composite outcome. by Basmah Safdar (12213257)

S1 Data - by Francois Kiemde (5369657)

“…A The downward regulation effect that both hormones have on each other during the pregnancy when each increase to 1 unit (1.0 ng/ml) was also reported.…”

Characteristic of study population. by Francois Kiemde (5369657)

“…A The downward regulation effect that both hormones have on each other during the pregnancy when each increase to 1 unit (1.0 ng/ml) was also reported.…”

Dynamics of cortisol levels measured in pregnant women during pregnancy determined at different ANC visits. by Francois Kiemde (5369657)

“…In both group, cortisol concentration increased in a sawtooth pattern during pregnancy with peaks at V2(28^th±1 week) and V4 32^th ±1 week), before decreasing at V5 which is part of post-partum.…”

JC-1 monomer increased with the stimulation of sFlt-1 and decreased after administration of Z-LEHD-FMK in HUVECs. by Yaling Zhai (9239458)

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects:

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 2. by Rahsan Erdem (11726357)

Subjects:

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Subjects: